Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Samuel Huse"'
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 3 (2022)
Background Atrial tachyarrhythmias are common after atrial fibrillation ablation, so adjunctive antiarrhythmic drug therapy is often used. Data on the effectiveness and safety of dronedarone and sotalol after AF ablation are limited. Here, we compare
Externí odkaz:
https://doaj.org/article/dc8e6e937419467e8de30dd575f7aa96
Autor:
Bo Ding, Rebecca Zaha, Naoyuki Makita, Sophie Graham, Dimitra Lambrelli, Samuel Huse, Hana Müllerová, Clementine Nordon, Shigeo Muro
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease. 18:247-258
Bo Ding,1 Rebecca Zaha,2 Naoyuki Makita,3 Sophie Graham,4,5 Dimitra Lambrelli,4 Samuel Huse,6 Hana Müllerová,7 Clementine Nordon,7 Shigeo Muro8 1BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden; 2Formerly of Data Analytics, Evidera,
Autor:
Emily P. Zeitler, Christopher J. Ronk, Alex Cockerham, Samuel Huse, David S. McKindley, Michael H. Kim
To summarize healthcare resource utilization (HCRU) in patients with newly diagnosed (incident) paroxysmal or persistent atrial fibrillation (AF). This retrospective, observational cohort study assessed HCRU among patients with incident paroxysmal or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf5da1388a7568244ce60a7b03a8d3ed
Publikováno v:
Diabetes. 70
This retrospective observational study using the Optum Clinformatics claims database included data from adults (≥18 y) with T2D who had received prior basal insulin (BI) (NPH, Gla-100, IDet) in the 6-month baseline period, and switched to either th
Publikováno v:
Drugs-Real World Outcomes
Background In 2014, the US Food and Drug Administration (FDA) initiated a prospective routine surveillance using the Mini-Sentinel (M-S) program to assess potential signals of acute myocardial infarction (AMI) and stroke with use of mirabegron, indic
Autor:
Abhishek Chitnis, Samuel Huse, Michael Stokes, Annette Lam, Don Robinson, Robert Z. Orlowski, Britte Kranenburg, Jianming He
Publikováno v:
European Journal of Haematology. 99:119-132
Objective The direct cost of relapsed or refractory multiple myeloma (RRMM) is documented; indirect costs are being explored. Healthcare payers seek cost-offsets from therapies that improve clinical outcomes but challenge budgets; employers seek lowe
Publikováno v:
Journal of the American College of Cardiology. 75:343
Adjunctive antiarrhythmic drug therapy is commonly used following catheter ablation of atrial fibrillation (AF). Data regarding their effectiveness for prevention of CV hosp after AF ablation are limited. We compared rates of CV hosp, repeat AF ablat
Autor:
Christina Cristaldi, Soulmaz Fazeli Farsani, Kimberly G. Brodovicz, Beth L. Nordstrom, Dana Y. Teltsch, Stefan Kaspers, Richard S. Swain, Samuel Huse
Publikováno v:
Pharmacoepidemiology and drug safety. 28(2)
Purpose To develop and validate algorithms to classify diabetes type in newly diagnosed pediatric patients with DM. Method Data from the United States Department of Defense health system were used to identify patients aged 10 to 18 years with inciden
Autor:
Naufil Alam, Ariel Berger, Walter W Grubb, John R. Wingard, Samuel Huse, Navneet S. Majhail, Samuel Dychter
Publikováno v:
Blood. 128:1187-1187
Background: Allogeneic HCT is a potentially curative procedure for many hematologic malignancies, but is associated with several complications. Acute GvHD is a condition that affects 35-50% of allogeneic HCT recipients, typically occurs within 100 da
Autor:
Wendy J. Levin, Moya Daniels, Walter W Grubb, Samuel Huse, Ariel Berger, Maitreyee Mohanty, John Ferraro
Publikováno v:
Blood. 126:4500-4500
Background: Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative option for many hematologic malignancies, but is associated with numerous complications, including infection. While the clinical consequences of infection post-